Last reviewed · How we verify

Caplyta — Competitive Intelligence Brief

Caplyta (Caplyta) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

marketed D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Caplyta (Caplyta) — University of Chicago.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Caplyta TARGET Caplyta University of Chicago marketed D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Caplyta — Competitive Intelligence Brief. https://druglandscape.com/ci/caplyta. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: